首页> 外文OA文献 >Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

【2h】

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

机译：CUDC-907的安全性，耐受性和初步活动，复发或难治性淋巴瘤或多发性骨髓瘤的患者中，HDAC和PI3K的一流，口服，双抑制剂：多种骨髓瘤：开放标签，剂量升级，阶段1审判

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Anas Younes; Jesus G Berdeja; Manish R Patel; Ian Flinn; John F Gerecitano; Sattva S Neelapu; Kevin R Kelly; Amanda R Copeland; Amy Akins; Myles S Clancy; Lucy Gong; Jing Wang; Anna Ma; Jaye L Viner; Yasuhiro Oki;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial [J] . Younes Anas, Berdeja Jesus G., Patel Manish R., The lancet oncology . 2016,第5期

机译：HDAC和PI3K的双重口服抑制剂CUDC-907在复发或难治性淋巴瘤或多发性骨髓瘤患者中的安全性，耐受性和初步活性：开放标签，剂量递增，1期试用
2. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study [J] . Stathis Anastasios, Flinn Ian W., Madan Sumit, Investigational new drugs. . 2018,第5期

机译：IMGN529的安全性，耐受性和初步活性，CD37靶向抗体 - 药物缀合物，复发或难治性B细胞非霍奇金淋巴瘤的患者：一种剂量升级，我研究
3. A Phase I Dose-Escalation Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Dual mTORC1/mTORC2 Kinase Inhibitor CC-223 in Patients With Advanced Solid Tumors or Multiple Myeloma [J] . Bendell Johanna C., Kelley Robin K., Shih Kent C., Cancer: A Journal of the American Cancer Society . 2015,第19期

机译：评估晚期实体瘤或多发性骨髓瘤患者双重mTORC1 / mTORC2激酶抑制剂CC-223的安全性，耐受性，药代动力学和初步疗效的I期剂量递增研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Phase 1 safety and dose escalation of CUDC-907 a first-in-class oral dual inhibitor of HDAC and PI3K in relapsed or refractory lymphoma and multiple myeloma [O] . Anas Younes, Jesus G. Berdeja, Manish R. Patel, -1

机译：CUDC-907是复发难治性淋巴瘤和多发性骨髓瘤中首个口服HDAC和PI3K双重抑制剂的第一阶段安全性和剂量递增
6. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial [O] . Vincent Chung, Aaron S. Mansfield, Fadi Braiteh, 2016

机译：患有固体瘤患者的LB-100，蛋白质磷酸酶2a抑制剂的安全性，耐受性和初步活性：开放标签，剂量升级，首先 - 人，I期试验

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

著录项

相似文献

相关主题

期刊订阅